<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00213980</url>
  </required_header>
  <id_info>
    <org_study_id>CO 99103</org_study_id>
    <nct_id>NCT00213980</nct_id>
  </id_info>
  <brief_title>Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer</brief_title>
  <official_title>Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two arm, double-blind randomized study looking at the effect of zoledronate, a
      bisphosphonate, on the bone mineral density (BMD) of postmenopausal women with breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two arm, double-blind randomized study looking at the effect of zoledronate, a
      bisphosphonate, on the bone mineral density (BMD) of postmenopausal women with breast cancer.
      An approved bisphosphonate, alendronate, is of benefit in patients with osteoporosis,
      however, this agent has a roughly 30% incidence of gastrointestinal symptoms and up to 50% of
      patients may take the drug improperly, compromising absorption and potentially efficacy.
      Zoledronate is a heterocyclic imidazole third generation bisphosphonate, which is
      administered intravenously (IV) and has little toxicity. Zoledronate is more potent than
      alendronate, and because of its route of administration it does not have the problems of poor
      oral bioavailability and non-compliance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bone Mineral Density (BMD) From Baseline to 1 Year</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>To determine whether zoledronate 4 mg IV every 12 weeks x 4 doses is associated with increases in bone mineral density at the lumbar spine and femoral head, calculated from baseline and 1 year data. Participants who missed one or more DXA were not evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of Metastases</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Determine whether zoledronate is associated in rates of bone, visceral, and all distant metastases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Number of participants who survived from the start of treatment through off treatment, up to 10 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Toxicity of ZA</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Tolerability and side effects of ZA, measured by the number of participants experiencing adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation only for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zoledronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zoledronate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronate</intervention_name>
    <description>4 mg IV over 15 minutes administered once every 12 weeks times 4</description>
    <arm_group_label>Zoledronate</arm_group_label>
    <other_name>Zometa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women, Stage III or axillary node positive

          -  Currently disease free of breast cancer and other invasive malignancies at the time of
             registration

          -  No concurrent use of bisphosphonates

        Exclusion Criteria:

          -  Metastatic disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Mulkerin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>August 2, 2017</results_first_submitted>
  <results_first_submitted_qc>December 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2018</results_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone mineral density</keyword>
  <keyword>postmenopausal women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The University of Wisconsin Comprehensive Cancer Center (UWCCC) conducted a clinical trial of adjuvant ZA in postmenopausal women with high-risk breast cancer, open through the Wisconsin Oncology Network (WON). Participants were recruited from 2000 through 2007.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Observation</title>
          <description>Observation only for 12 months</description>
        </group>
        <group group_id="P2">
          <title>Zoledronic Acid (ZA)</title>
          <description>ZA
Zoledronic acid (ZA): 4 mg IV over 15 minutes administered once every 12 weeks for 4 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Developed ovarian cancer</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to obtain all 3 DXAs</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Postmenopausal women with stage II/III breast cancer diagnosed up to 5 years previous.</population>
      <group_list>
        <group group_id="B1">
          <title>Observation</title>
          <description>Observation only for 12 months</description>
        </group>
        <group group_id="B2">
          <title>Zoledronic Acid (ZA)</title>
          <description>ZA
Zoledronic acid (ZA): 4 mg IV over 15 minutes administered once every 12 weeks for 4 cycles</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" lower_limit="37" upper_limit="65"/>
                    <measurement group_id="B2" value="54.5" lower_limit="41" upper_limit="83"/>
                    <measurement group_id="B3" value="52.5" lower_limit="37" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Size</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>=&lt; 2cm</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2.1cm - 5cm</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 5cm</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Inflammatory</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lymph Node Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Node negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Node positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Endocrine Therapy During Year 1 on Study</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Tamoxifen or other SERM</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Aromatase Inhibitor (AI)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Tamoxifen switched to AI during study year</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No data available</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Performance Status</title>
          <description>Participants were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. ECOG performance is used to assess how a participant's disease is progressing, assess how the disease affects daily living abilities, and determine appropriate treatment and prognosis. A score of 0 is &quot;fully active, able to carry on all pre-disease performance without restriction,&quot; and 2 is &quot;ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Bone Mineral Density (BMD) From Baseline to 1 Year</title>
        <description>To determine whether zoledronate 4 mg IV every 12 weeks x 4 doses is associated with increases in bone mineral density at the lumbar spine and femoral head, calculated from baseline and 1 year data. Participants who missed one or more DXA were not evaluated.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Fifty-six participants (ZA = 29, Observation = 27) were evaluable based on completing DXAs at 0, 6, and 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid (ZA)</title>
            <description>ZA
Zoledronic acid (ZA): 4 mg IV over 15 minutes administered once every 12 weeks for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Observation only for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bone Mineral Density (BMD) From Baseline to 1 Year</title>
          <description>To determine whether zoledronate 4 mg IV every 12 weeks x 4 doses is associated with increases in bone mineral density at the lumbar spine and femoral head, calculated from baseline and 1 year data. Participants who missed one or more DXA were not evaluated.</description>
          <population>Fifty-six participants (ZA = 29, Observation = 27) were evaluable based on completing DXAs at 0, 6, and 12 months.</population>
          <units>grams per cubic centimeter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lumbar Spine L1-L4 (L1-L4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.048" lower_limit="0.034" upper_limit="0.062"/>
                    <measurement group_id="O2" value="0.007" lower_limit="-0.020" upper_limit="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral neck (FN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.014" lower_limit="0.002" upper_limit="0.027"/>
                    <measurement group_id="O2" value="0.005" lower_limit="-0.012" upper_limit="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total femur (TF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019" lower_limit="0.011" upper_limit="0.026"/>
                    <measurement group_id="O2" value="0.004" lower_limit="-0.006" upper_limit="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trochanter (T)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023" lower_limit="0.013" upper_limit="0.34"/>
                    <measurement group_id="O2" value="0.005" lower_limit="-0.007" upper_limit="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcaneal (OC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" lower_limit="0.004" upper_limit="0.015"/>
                    <measurement group_id="O2" value="0.001" lower_limit="-0.007" upper_limit="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Metastases</title>
        <description>Determine whether zoledronate is associated in rates of bone, visceral, and all distant metastases.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Data for this outcome measure was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid (ZA)</title>
            <description>ZA
Zoledronic acid (ZA): 4 mg IV over 15 minutes administered once every 12 weeks for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Observation only for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Metastases</title>
          <description>Determine whether zoledronate is associated in rates of bone, visceral, and all distant metastases.</description>
          <population>Data for this outcome measure was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Number of participants who survived from the start of treatment through off treatment, up to 10 years.</description>
        <time_frame>Up to 10 years</time_frame>
        <population>Only participants who completed the trial (ZA = 29 and Observation = 26) were analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid (ZA)</title>
            <description>ZA
Zoledronic acid (ZA): 4 mg IV over 15 minutes administered once every 12 weeks for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Observation only for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Number of participants who survived from the start of treatment through off treatment, up to 10 years.</description>
          <population>Only participants who completed the trial (ZA = 29 and Observation = 26) were analyzed for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Toxicity of ZA</title>
        <description>Tolerability and side effects of ZA, measured by the number of participants experiencing adverse events.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Data was collected for the ZA arm at 9 time points, and for the Observation arm at 2 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid (ZA)</title>
            <description>ZA
Zoledronic acid (ZA): 4 mg IV over 15 minutes administered once every 12 weeks for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Observation only for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Toxicity of ZA</title>
          <description>Tolerability and side effects of ZA, measured by the number of participants experiencing adverse events.</description>
          <population>Data was collected for the ZA arm at 9 time points, and for the Observation arm at 2 time points.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for up to 48 weeks.</time_frame>
      <desc>Toxicity evaluation including telephone assessment occurred at 1 week after the start of each cycle.
Toxicities for the Zoledronate arm were assessed at 9 time points, and toxicities for the Observation arm were assessed at 2 time points.</desc>
      <group_list>
        <group group_id="E1">
          <title>Observation</title>
          <description>Observation only for 12 months</description>
        </group>
        <group group_id="E2">
          <title>Zoledronic Acid (ZA)</title>
          <description>ZA
Zoledronic acid (ZA): 4 mg IV over 15 minutes administered once every 12 weeks for 4 cycles</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flash</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="32"/>
                <counts group_id="E2" events="36" subjects_affected="20" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="30" subjects_affected="15" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="70" subjects_affected="27" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="26" subjects_affected="20" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" events="54" subjects_affected="28" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheaded</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Mulkerin</name_or_title>
      <organization>University of Wisconsin Carbone Cancer Center</organization>
      <phone>608-265-8090</phone>
      <email>dm2@medicine.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

